BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 18, 2026
Home » Blogs » BioWorld MedTech Perspectives » FDA, devices and doom and gloom

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Diagnostics / CDRH / FDA

FDA, devices and doom and gloom

May 25, 2011
By Mark McCarty

Is the sky falling? Device makers keep saying so

By MARK McCARTY

Medical Device Daily Washington Editor

FDA's Center for Devices and Radiological Health is certainly on a regulatory tear of late, and industry is understandably rattled by some of the developments. After all, CDRH only recently managed to shed a couple of obvious malcontents in the persons of Robert Smith, MD, and Julian Nichols, MD, who both worked at the Office of Device Evaluation at CDRH and were not exactly happy to get their walking papers. My impression is that you have to be either really obnoxious, noticeably incompetent, or both to lose a job with Uncle Sam, so it's difficult to avoid the conclusion that these two had some serious baggage and went out of their way to make trouble.

Even without the aforementioned renegades, industry has a lot of gripes about how things are done at CDRH, which is notoriously underfunded and unable to keep pace with everything that lands in its lap. Still, industry has a bad habit of declaring small device makers an endangered species. This didn't seem entirely speculative in early 2009, when the economy tottered on the verge of collapse. Back then, changes were on the horizon at FDA, venture capital looked nervous, and the U.S. Patent and Trademark Office was bogged down with roughly three quarters of a million patent applications with an average pendency of 36 months.

Things have stabilized since then, but the doomsday talk hasn't abated. For instance, I recently interviewed the principal of a small device firm who said industry was carefully watching the fate of his company's application and that a failure by FDA to approve the application would have “dire” consequences for the entire industry.

To some extent, a reworking of the approval and clearance processes at CDRH was needed, although some of the proposals put forth by the agency seem a bit off the charts. All the same, this business of saying in more or less veiled terms that the sky is falling is just absurd. When you look at per-capita income in the U.S. and the sheer amounts spent on healthcare here, the concept that device makers will utterly abandon the U.S. is just silly. And claiming industry will bail out is dishonest, because we all know better.

Just for the record, I don't go to church – not routinely anyway – and haven't since the age of 15, so I can't say for certain I'd know the Crack of Doom if I heard it. All the same, I'm not deaf, and I know that even in the face of Euro-flight, device makers will still want and need the U.S. market for at least as long as any of us are alive. After all, who can say no to a market measured in the trillions of dollars?

So please industry, no more apocalyptic forecasts. It's getting old. Not interesting, just old.

Is this really necessary?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing